Anew Labs

Anew Labs is an AI-driven drug discovery company that spun out of Chinese tech giant ByteDance in June 2026. The company leverages a suite of proprietary generative AI models, including AnewFold, AnewSampling, AnewOmni, AnewDesign, and AnewMind, to predict protein structures, design antibodies, and generate small molecules for challenging therapeutic targets. Anew Labs' lead program is an orally bioavailable pan-IL-17 small-molecule inhibitor designed to block all three dimers of the IL-17 family (AA, AF, and FF) for the treatment of autoimmune and inflammatory diseases. With a core team of researchers and drug development experts, the company operates a closed-loop discovery engine combining computational design with wet-lab validation.